Intranasal treatment with C57BL/6 MSCs reduces lesion volume and improves motor and @entity73 in the neonatal @entity63 ( @entity63 ) @entity19 model. In this study, we investigated the potential of @entity1 MSCs (hMSCs) to treat @entity63 @entity1545 in the neonatal @entity19 . Assessing the regenerative capacity of hMSCs is crucial for translation of our knowledge to the clinic. We determined the neuroregenerative potential of hMSCs in vitro and in vivo by intranasal administration 10 d post- @entity63 in neonatal @entity19 . @entity63 was induced in P9 @entity19 pups. 1*10(6) or 2*10(6) hMSCs were administered intranasally 10 d post- @entity63 . Motor behavior and lesion volume were measured 28 d post- @entity63 . The in vitro capacity of hMSCs to induce differentiation of @entity19 neural stem cell (mNSC) was determined using a transwell co-culture differentiation assay. To determine which chemotactic factors may play a role in mediating migration of MSCs to the lesion, we performed a PCR array on 84 chemotactic factors 10 days following sham-operation, and at 10 and 17 days post- @entity63 . Our results show that 2*10(6) hMSCs decrease lesion volume, improve motor behavior, and reduce scar formation and microglia activity. Moreover, we demonstrate that the differentiation assay reflects the neuroregenerative potential of hMSCs in vivo, as hMSCs induce mNSCs to differentiate into neurons in vitro. We also provide evidence that the chemotactic factor @entity15369 may play an important role in hMSC migration to the lesion site. This is suggested by our finding that @entity15369 is significantly upregulated at 10 days following @entity63 , but not at 17 days after @entity63 , a time when MSCs no longer reach the lesion when given intranasally. The results described in this work also tempt us to contemplate hMSCs not only as a potential treatment option for neonatal @entity75 , but also for a plethora of degenerative and @entity4215 .

Intranasal administration of XXXX MSC for ischemic brain injury in the @entity19 : in vitro and in vivo neuroregenerative functions.

@entity1 :: ('9606', 'Species') :: ['human'] @entity1545 :: ('MESH:D020214', 'Disease') :: ['brain injury'] @entity4215 :: ('MESH:D020196', 'Disease') :: ['traumatic injuries of the nervous system'] @entity63 :: ('MESH:D007511', 'Disease') :: ['HI', 'hypoxic-ischemic'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive behavior'] @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy'] @entity15369 :: ('15945(Tax:10090)', 'Gene') :: ['CXCL10']
@entity1 :: (9606,Species) :: ['human']
